Martin Mertens

IRRAS AB

Founded in Sweden in 2012, IRRAS is a commercial medical device company, focused on designing, developing, and commercializing innovative solutions that transform fluid management after surgical procedures. Our initial clinical focus is on intracranial procedures, where excess cerebrospinal fluid (CSF) often needs to be drained and intracranial pressure (ICP) needs to be closely regulated. IRRAS' first commercial product, IRRAflow®, is a next generation intracranial fluid exchange system that consists of a patented dual lumen catheter and control unit with proprietary software that work together to manage the drainage of excess fluid, intelligently manage the regulation of the patient's ICP, and, on a regular basis, proactively flush the catheter to prevent occlusions from forming. These catheter blockages occur up to 40% of the time with legacy drainage systems and can result in inefficient drainage and excessively high infection rates, and IRRAflow's intelligent fluid exchange helps to address these shortcomings and provide a new standard of care for how Neuro ICU patients are managed. Through continued technological advances, we remain focused on developing innovative features for IRRAflow as well as new products based on our core fluid exchange technologies. In the future, we envision new therapeutic applications for the IRRAflow platform, including targeted drug delivery and drainage in other clinical areas, such as abdominal surgery. IRRAS is traded on the NASDAQ First North Premier exchange in Stockholm under the symbol IRRAS and is headquartered in Stockholm, Sweden, with offices in Munich, Germany, and San Diego, California.